LS-P-START

A Phase 1/1b, First-In-Human, Multi-Part, Open-Label Trial To Investigate The Safety, Tolerability, Pharmacokinetics, Biological And Clinical Activity Of Df6215 In Patients With Advanced (Unresectable, Recurrent, Or Metastatic) Solid Tumors